Symphogen Selects TransPerfect's Trial Interactive eTMF Technology And Services
NEW YORK, /PRNewswire/ -- TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that Symphogen has selected TransPerfect's Trial Interactive eTMF and supporting TMF services to centralize and streamline operations for current and future studies.
Based in Copenhagen, Denmark, Symphogen is a private, late-stage clinical oncology-focused company with a novel and differentiated antibody mixture pipeline. Specifically, they are pioneering the application of mAb mixtures as an innovative approach to cancer therapy. As the company progresses with their clinical programs, including an anticipated Phase 3 study, Symphogen will leverage Trial Interactive's eTMF and TMF services for greater control of TMF quality and health, and to support scalability throughout their current growth. Among these organizational goals, Symphogen is also focused on enhancing CRO/sponsor collaboration with a secure environment to manage multiple roles and relationships.
The Trial Interactive e-clinical platform was designed by clinical professionals, for clinical professionals. It is used by pharmaceutical, biotechnology, and CRO companies to streamline product development lifecycles in a secure, 21 CFR Part 11-compliant environment. By offering a fully integrated experience, Trial Interactive improves speed and quality across site identification, site selection, personnel training, study start-up, and site activation, through eTMF management and closeout. The Trial Interactive platform delivers nuanced, clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
Michael Smyth, Division President of TransPerfect Life Sciences Solutions, stated, "Our aim is to enable growth for our clients and their clinical teams by providing leading technology and expert-driven services. Symphogen's initiative to bring their eTMF system and management in-house is a perfect application of our e-clinical solutions that will have a significant benefit for their team and workflows."
TransPerfect President and CEO, Phil Shawe, added, "The work that Symphogen does for cancer patients is critically important, and it's rewarding to know that our technology and services play a role in helping them bring potentially life-changing treatments to market in the most efficient manner possible."
About Trial Interactive
View original content to download multimedia:http://www.prnewswire.com/news-releases/symphogen-selects-transperfects-trial-interactive-etmf-technology-and-services-300745188.html